Market Overview

Insider Buys Of The Week: Allergan, American Homes 4 Rent, Tiffany

Share:
Insider Buys Of The Week: Allergan, American Homes 4 Rent, Tiffany
Related AGN
The Daily Biotech Pulse: Pfizer And Allergan Earnings, CFO Departures At Acadia And Assertio
Earnings Scheduled For October 30, 2018
Related AMH
Benzinga's Top Upgrades, Downgrades For November 19, 2018
Insider Buys Of The Week: American Homes 4 Rent, Bunge, Platform Specialty Products
Beware Wall Street's Stupid Narrative, Invitation Homes Is A Buy (Seeking Alpha)

Insider buying can be an encouraging signal for potential investors.

A couple insiders were buying shares near 52-week highs.

Another insider more than doubled a stake in the past week.

  • Conventional wisdom says that insiders and 10-percent owners only buy shares of a company for one reason — they believe the stock price will rise and they want to profit. So insider buying can be an encouraging signal for potential investors, particularly with markets at all-time highs.

Here's a look at a few notable insider purchases reported in the past week.

American Homes 4 Rent

American Homes 4 Rent (NYSE: AMH) saw two directors step up to the buy window this past week. The approximately 434,000 shares of this real estate investment trust that were acquired at per-share prices ranging from $22.72 to $23.22 3 altogether cost the directors nearly $9.97 million. Each of those directors has a stake of more than 13 million shares.

Shares of American Homes 4 Rent were hitting new 52-week highs as August came to a close. The stock ended the week trading at $22.87, still within the directors' purchase price range. The stock has changed hands between $18.39 and $23.34 in the past year, and the analyst's mean price target is $24.98.

Allergan

Allergan plc (NYSE: AGN) saw a director more than double a stake last week. The 10,000 shares of this pharmaceutical company acquired, at per-share prices between $190.55 and $190.68, cost him more than $1.9 million. And note that two other directors also bought smaller batches of shares at the end of August.

Allergan got a snub from the FDA in August for its treatment of abnormal uterine bleeding. Its shares slipped less than 1 percent in the past week, and they were last seen trading at $190.24 apiece. That was less than the director's purchase price. The stock has traded as high as $237.41 a share in the past year, but the analysts' mean price target is $210.15.

Tiffany

A Tiffany & Co. (NYSE: TIF) director has picked up 50,000 shares of this luxury goods retailer so far this month. The share prices for these purchases ranged from $121.49 to $124.87, and the transactions totaled more than $6.19 million. Note that the transactions included some unvested restricted stock units.

Tiffany recently posted better-than-expected second-quarter results. The share price slipped about 2 percent but mostly recovered during the past week and closed on Friday at $122.87. While the stock has traded as high as $141.64 a share in the past year, the analysts' mean price target is $140.50.

See also: 7 Reasons Eccentric Elon Musk Does What He Does

At the time of this writing, the author had no position in the mentioned equities.

Keep up with all the latest breaking news and trading ideas by following Benzinga on Twitter.

Posted-In: News Insider Trades Best of Benzinga

 

Related Articles (AGN + AMH)

View Comments and Join the Discussion!

Benzinga's Bulls & Bears Of The Week: Apple, Facebook, Nike, Tesla, More

The Week Ahead In Biotech: Conferences, Clinical Trial Results, Earnings And IPOs